This designation is meaningful as it signifies our continued commitment to making biosimilars more accessible. Both biosimilars and interchangeable biosimilars are highly similar and have no ...

Rocket Pharmaceuticals halted its Danon disease gene therapy trial after a patient death, with the FDA placing the study on clinical hold for review.

RxDx assay as a companion diagnostic to identify c-Met protein expression in non-squamous NSCLC patients eligible for treatment with Emrelis.

Biotech company AbbVie (ABBV) said on Wednesday that the U.S. Food and Drug Administration has approved Emrelis medicine for ...

No drug-related decreases in platelet counts ... of immunofluorescence analyses in our study. In conclusion, systemic administration of PRO051 resulted in dose-dependent, abundant expression ...

Importing foreign price controls via President Trump’s MFN scheme is not the answer. They risk patients access and ...